Özet:

Introduction: In prematural babies, especially in those with very low birth weight (CDD) the improvement of the quality of care resulted in the rise in survival rates, the rise in prematurity-related morbidities. Patent duktus arteriosis (PDA) and proper management of associated complications (such as conjunctive heart failure, bronchopulmonary dysplasia, necrotic enterocolitis, intrakranial bleeding and death), which is one of these morbidities, is very important for the improvement of short and long-term results. Therefore, it is important that the hemodynamic meaningful PDA (HAPDA) is treated in time and effectively. Purpose: In this study, the aim is to retrospective assess the results of premature babies in post-reaction bed bed bed surgery PDA ligation to the medical closure treatment applied with the diagnosis of HAPDA. Metaryal and Method In this retrospective study, the results of babies applied PDA ligation in bed bed surgery with the diagnosis of HAPDA in the newborn intensive care unit (YYBU) were evaluated retrospective. 84 premature babies were included in the study. Demographic characteristics, the type and duration of respiratory support before and after surgery, intraventricular bleeding and bronkopulmonary dysplasia rates, the duration of hospital stay and mortality data were analyzed.   The results included 84 premature infant in the study. HAPDA diagnosed with 61 (% 72. 6) infanta was closed with medical treatment, 23 (27.4%) infanta was applied with surgical ligation.  The age of surgery was 35 (25-46) days, the body weight of the surgery was 1150 gr (870-1100 gr) on the day of surgery. In the group applied for the surgical ligation, about 60 days after the application, a baby (4.3%) was lost (sindromic infant), 22 babies were able to be dismissed. The periods of breathing support, oxygen cuts and discharge in babies in need of ligation have been statically significantly longer compared to babies responding to medical treatment (p<0.001). In the bed bed bed surgery ligation, no complications related to surgery were observed. The result:

Anahtar Kelimeler:

Özet:

The appropriate management of patent ductus arteriosus (PDA) and associated complications (such as congestive heart failure, bronchopulmonary dysplasia, necrotizing enterocolitis, intracranial hemorrhage and death), which is one of these morbidities, is very important for the improvement of short and long-term results. Aim The aim of this study was to retrospectively evaluate the results of premature infants who underwent bedside surgery PDA ligation after a non-responding medical closure therapy. Methods In this retrospective study, the results of babies who underwent bedside surgical PDA ligation with the diagnosis of HAPDA in the neonatal intensive care unit (NICU) were evaluated retrospectively. 84 premature babies were included in the study. Demographic characteristics, type and duration of pre- and postoperative respiratory support, intraventricular hemorrhage and bronchopulmonary dysplasia rates, hospital stay duration and mortality data were analyzed. Results 84 premature infants were included in the study. In 61 infants (72.6%) closure with medical treatment and surgical ligation in 23 infants (27.4%) were performed with the diagnosis of HAPDA. The median operating age was 35 (25-46) days and the median body weight on the day of surgery was 1150 g (870-1100 g). In the group undergoing surgical ligation, a baby (4.3%) was lost about 60 days after the administration, while 22 infants could be discharged. Respiratory support, oxygen withdrawal and discharge time of the babies who needed ligation were statistically significantly longer than those responding to medical treatment (p <0.001). No complication related to surgery was observed in infants who underwent bed ligand surgery. Conclusions The prolonged patency of the ductus arteriosus in preterm infants is related to an increased morbidity. Bedside PDA ligation in NICUs where there is no pediatric cardiovascular surgery team should be kept in mind as an alternative safe method to reduce PDA-related morbidity and mortality by preventing delay in treatment in patients who do not respond to medical treatment.